Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives.
Gringeri E, Furlanetto A, Billato I, Cescon M, De Carlis L, Mazzaferro V, Romagnoli R, De Simone P, Vivarelli M, Di Benedetto F, Ravaioli M, Lauterio A, Sposito C, Patrono D, Ghinolfi D, Moccheggiani F, Di Sandro S, D'Amico FE, Lanari J, Gambato M, Trapani S, Bergamo F, Cardillo M, Burra P, Cillo U. Gringeri E, et al. Among authors: bergamo f. Updates Surg. 2024 Aug 29. doi: 10.1007/s13304-024-01889-1. Online ahead of print. Updates Surg. 2024. PMID: 39210194
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling.
Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, Zagonel V, Fassan M, Rosato A, Lonardi S. Bergamo F, et al. Front Oncol. 2022 Dec 8;12:964219. doi: 10.3389/fonc.2022.964219. eCollection 2022. Front Oncol. 2022. PMID: 36578937 Free PMC article.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: bergamo f. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6. BMC Cancer. 2024. PMID: 38589856 Free PMC article. Clinical Trial.
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience.
Moretto R, Germani MM, Borelli B, Conca V, Rossini D, Boraschi P, Donati F, Urbani L, Lonardi S, Bergamo F, Cerma K, Ramondo G, D'Amico FE, Salvatore L, Valente G, Barbaro B, Giuliante F, Di Maio M, Masi G, Cremolini C. Moretto R, et al. Among authors: bergamo f. ESMO Open. 2024 Apr;9(4):102991. doi: 10.1016/j.esmoop.2024.102991. Epub 2024 Apr 16. ESMO Open. 2024. PMID: 38631269 Free PMC article.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: bergamo f. BMC Cancer. 2024 May 6;24(1):563. doi: 10.1186/s12885-024-12328-0. BMC Cancer. 2024. PMID: 38711003 Free PMC article. No abstract available.
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Cremolini C, et al. Among authors: bergamo f. Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13. Eur J Cancer. 2017. PMID: 27986363
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Cremolini C, et al. Among authors: bergamo f. Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13. Br J Cancer. 2018. PMID: 29531324 Free PMC article.
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?
Loupakis F, Schirripa M, Intini R, Bergamo F, Bertorelle R, Fassan M, Dadduzio V, Merigliano S, Pilati P, Urso ELD, Cillo U, Rugge M, Lonardi S, Zagonel V. Loupakis F, et al. Among authors: bergamo f. Oncologist. 2019 Feb;24(2):e77-e79. doi: 10.1634/theoncologist.2018-0180. Epub 2018 Aug 17. Oncologist. 2019. PMID: 30120156 Free PMC article.
217 results